Evidence map›Paper›PMID 39473682›Full record

ArticleCureus2024

Gilteritinib-Induced Hypopituitarism: A Case Report.

Yuri Hori, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Yoshiya Tanaka

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuri HoriInternal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Yosuke OkadaInternal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Satomi SonodaInternal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Keiichi TorimotoInternal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Yoshiya TanakaInternal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gilteritinib is a tyrosine kinase inhibitor (TKI) that treats acute myeloid leukemia (AML) by inhibiting FMS-like tyrosine kinase 3 (FLT3). This is a report on hypopituitarism induced by gilteritinib and its resolution following withdrawal. A 54-year-old woman was treated with gilteritinib for AML. She subsequently developed general fatigue. Blood tests showed low levels of anterior pituitary hormone. After 10 months of gilteritinib withdrawal, the levels of anterior pituitary hormones returned to normal values. When nonspecific symptoms such as fatigue in patients treated with gilteritinib are coupled with electrolyte abnormalities, a close checkup for hypopituitarism is recommended.

Indexed as

acute myeloid leukemiadrug withdrawalgilteritinibhypopituitarismpituitary hormone

Identifiers

PMID39473682
PMCPMC11518918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.